Cargando…

P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells

BACKGROUND: P-selectin glycoprotein ligand-1 (PSGL-1/CD162) has been studied extensively for its role in mediating leukocyte rolling through interactions with its cognate receptor, P-selectin. Recently, PSGL-1 was identified as a novel HIV-1 host restriction factor, particularly when expressed at hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnie, Jonathan, Persaud, Arvin Tejnarine, Thaya, Laxshaginee, Liu, Qingbo, Miao, Huiyi, Grabinsky, Stephen, Norouzi, Vanessa, Lusso, Paolo, Tang, Vera A., Guzzo, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123692/
https://www.ncbi.nlm.nih.gov/pubmed/35597982
http://dx.doi.org/10.1186/s12977-022-00593-5
_version_ 1784711604612366336
author Burnie, Jonathan
Persaud, Arvin Tejnarine
Thaya, Laxshaginee
Liu, Qingbo
Miao, Huiyi
Grabinsky, Stephen
Norouzi, Vanessa
Lusso, Paolo
Tang, Vera A.
Guzzo, Christina
author_facet Burnie, Jonathan
Persaud, Arvin Tejnarine
Thaya, Laxshaginee
Liu, Qingbo
Miao, Huiyi
Grabinsky, Stephen
Norouzi, Vanessa
Lusso, Paolo
Tang, Vera A.
Guzzo, Christina
author_sort Burnie, Jonathan
collection PubMed
description BACKGROUND: P-selectin glycoprotein ligand-1 (PSGL-1/CD162) has been studied extensively for its role in mediating leukocyte rolling through interactions with its cognate receptor, P-selectin. Recently, PSGL-1 was identified as a novel HIV-1 host restriction factor, particularly when expressed at high levels in the HIV envelope. Importantly, while the potent antiviral activity of PSGL-1 has been clearly demonstrated in various complementary model systems, the breadth of PSGL-1 incorporation across genetically diverse viral isolates and clinical isolates has yet to be described. Additionally, the biological activity of virion-incorporated PSGL-1 has also yet to be shown. RESULTS: Herein we assessed the levels of PSGL-1 on viruses produced through transfection with various amounts of PSGL-1 plasmid DNA (0–250 ng), compared to levels of PSGL-1 on viruses produced through infection of T cell lines and primary PBMC. We found that very low levels of PSGL-1 plasmid DNA (< 2.5 ng/well) were necessary to generate virus models that could closely mirror the phenotype of viruses produced via infection of T cells and PBMC. Unique to this study, we show that PSGL-1 is incorporated in a broad range of HIV-1 and SIV isolates and that virions with incorporated PSGL-1 are detectable in plasma from viremic HIV-1-infected individuals, corroborating the relevance of PSGL-1 in natural infection. Additionally, we show that PSGL-1 on viruses can bind its cognate selectin receptors, P-, E-, and L-selectins. Finally, we show viruses with endogenous levels of PSGL-1 can be captured by P-selectin and transferred to HIV-permissive bystander cells, highlighting a novel role for PSGL-1 in HIV-1 infection. Notably, viruses which contained high levels of PSGL-1 were noninfectious in our hands, in line with previous findings reporting the potent antiviral activity of PSGL-1. CONCLUSIONS: Our results indicate that levels of PSGL-1 incorporation into virions can vary widely among model systems tested, and that careful tailoring of plasmid levels is required to recapitulate physiological systems when using pseudovirus models. Taken together, our data suggest that PSGL-1 may play diverse roles in the physiology of HIV-1 infection, particularly due to the functionally active state of PSGL-1 on virion surfaces and the breadth of PSGL-1 incorporation among a wide range of viral isolates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-022-00593-5.
format Online
Article
Text
id pubmed-9123692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91236922022-05-21 P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells Burnie, Jonathan Persaud, Arvin Tejnarine Thaya, Laxshaginee Liu, Qingbo Miao, Huiyi Grabinsky, Stephen Norouzi, Vanessa Lusso, Paolo Tang, Vera A. Guzzo, Christina Retrovirology Research BACKGROUND: P-selectin glycoprotein ligand-1 (PSGL-1/CD162) has been studied extensively for its role in mediating leukocyte rolling through interactions with its cognate receptor, P-selectin. Recently, PSGL-1 was identified as a novel HIV-1 host restriction factor, particularly when expressed at high levels in the HIV envelope. Importantly, while the potent antiviral activity of PSGL-1 has been clearly demonstrated in various complementary model systems, the breadth of PSGL-1 incorporation across genetically diverse viral isolates and clinical isolates has yet to be described. Additionally, the biological activity of virion-incorporated PSGL-1 has also yet to be shown. RESULTS: Herein we assessed the levels of PSGL-1 on viruses produced through transfection with various amounts of PSGL-1 plasmid DNA (0–250 ng), compared to levels of PSGL-1 on viruses produced through infection of T cell lines and primary PBMC. We found that very low levels of PSGL-1 plasmid DNA (< 2.5 ng/well) were necessary to generate virus models that could closely mirror the phenotype of viruses produced via infection of T cells and PBMC. Unique to this study, we show that PSGL-1 is incorporated in a broad range of HIV-1 and SIV isolates and that virions with incorporated PSGL-1 are detectable in plasma from viremic HIV-1-infected individuals, corroborating the relevance of PSGL-1 in natural infection. Additionally, we show that PSGL-1 on viruses can bind its cognate selectin receptors, P-, E-, and L-selectins. Finally, we show viruses with endogenous levels of PSGL-1 can be captured by P-selectin and transferred to HIV-permissive bystander cells, highlighting a novel role for PSGL-1 in HIV-1 infection. Notably, viruses which contained high levels of PSGL-1 were noninfectious in our hands, in line with previous findings reporting the potent antiviral activity of PSGL-1. CONCLUSIONS: Our results indicate that levels of PSGL-1 incorporation into virions can vary widely among model systems tested, and that careful tailoring of plasmid levels is required to recapitulate physiological systems when using pseudovirus models. Taken together, our data suggest that PSGL-1 may play diverse roles in the physiology of HIV-1 infection, particularly due to the functionally active state of PSGL-1 on virion surfaces and the breadth of PSGL-1 incorporation among a wide range of viral isolates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-022-00593-5. BioMed Central 2022-05-21 /pmc/articles/PMC9123692/ /pubmed/35597982 http://dx.doi.org/10.1186/s12977-022-00593-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Burnie, Jonathan
Persaud, Arvin Tejnarine
Thaya, Laxshaginee
Liu, Qingbo
Miao, Huiyi
Grabinsky, Stephen
Norouzi, Vanessa
Lusso, Paolo
Tang, Vera A.
Guzzo, Christina
P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title_full P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title_fullStr P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title_full_unstemmed P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title_short P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
title_sort p-selectin glycoprotein ligand-1 (psgl-1/cd162) is incorporated into clinical hiv-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123692/
https://www.ncbi.nlm.nih.gov/pubmed/35597982
http://dx.doi.org/10.1186/s12977-022-00593-5
work_keys_str_mv AT burniejonathan pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT persaudarvintejnarine pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT thayalaxshaginee pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT liuqingbo pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT miaohuiyi pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT grabinskystephen pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT norouzivanessa pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT lussopaolo pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT tangveraa pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells
AT guzzochristina pselectinglycoproteinligand1psgl1cd162isincorporatedintoclinicalhiv1isolatesandcanmediateviruscaptureandsubsequenttransfertopermissivecells